Voruciclib is an orally active, selective cyclin-dependent kinase (CDK) inhibitor. It effectively inhibits CDK9, a key regulator of MCL-1 transcription. In various diffuse large B-cell lymphoma (DLBCL) models, Voruciclib suppresses MCL-1 expression. This compound is significant in PROTAC development due to its ability to selectively inhibit CDKs and modulate transcriptional regulation. Reagent grade, for research use only.
Usually ships within 24 hours.